Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientif...( BOSTON Sept. 14 /- The 13th Ann...),Health

BOSTON, Sept. 14 /PRNewswire/ -- The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston. The three-day meeting serves as a forum for heart failure specialists to present research findings and advances in treatment and addresses emerging trends in research and new developments in the approach to treating heart failure patients. Four late breaking trials were presented today:

• Improving evidence based care for heart failure in outpatient cardiology practices: Primary results of IMPROVE HF. This trial tested the effect of a practice specific performance improvement intervention on quality measure in pts with HF in outpatient cardiology practices. The IMPROVE HF initiative resulted in substantial improvements in use of evidence-based therapies in eligible patients with systolic HF in outpatient cardiology practices. Implementation of a defined and scalable practice specific intervention enhances use of guideline-recommended HF therapies demonstrated to improve outcomes.
• Reduction in the risk of heart failure with preventative cardiac resynchronization therapy: MADIT - CRT Trial. This trial was designed to determine if prophylactic CRT with defibrillator would reduce the primary endpoint in all cause mortality or HF events (IV diuretic therapy or hospitalization for HF), whichever occurred first, when compared to patients receiving only an implanted cardiac defibrillator. The results of MADIT-CRT suggest that the use of CRT in asymptomatic or mildly symptomatic cardiac patients with a reduced EF and wide QRS complex is associated with a significant 29% decrease in the risk of death or HF. The benefit of CRT-D in this population was driven by a reduction in heart failure events.
• Superior performance of intrathoracic impedance-derived fluid index versus daily weight moni
  '/>"/>